(Reuters) – Swiss drugmaker Novartis AG (S:) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (O:) for about $7 billion, the Wall Street Journal reported on Saturday.
The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the matter.
Neither Novartis nor The Medicines Co were immediately available for comment on Saturday.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.